

References for Mark Lewis Board Review Q&A

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.

Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Lorient MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C; Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO- Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNP Gx). Fundam Clin Pharmacol. 2015 Jun;29(3):219-37. doi: 10.1111/fcp.12117. Epub 2015 May 4.

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

Diasio RB, Beavers TL, Carpenter JT. J Clin Invest. 1988 Jan;81(1):47-51.

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.

Harris BE, Carpenter JT, Diasio RB. Cancer. 1991 Aug 1;68(3):499-501.

Response to 5-fluorouracil chemotherapy is modified by dietary folic acid deficiency in Apc(Min/+) mice.

Tucker JM, Davis C, Kitchens ME, Bunni MA, Priest DG, Spencer HT, Berger FG. Cancer Lett. 2002 Dec 10;187(1-2):153-62. Erratum in: Cancer Lett. 2003 Dec 8;202(1):119.

Identification of patients with high-risk stage II colon cancer for adjuvant therapy.

Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR. Dis Colon Rectum. 2008 May;51(5):503-7

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. J Clin Oncol. 2004 May 15;22(10):1797-806.

Adherence to stage-specific treatment guidelines for patients with colon cancer.

Chagpar R, Xing Y, Chiang YJ, Feig BW, Chang GJ, You YN, Cormier JN. J Clin Oncol. 2012 Mar 20;30(9):972-9. doi: 10.1200/JCO.2011.39.6937. Epub 2012 Feb 21.

Carcinoma of the colon and rectum.

Hamilton SR, Bosman FT, Boffetta P, et al. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman FT, Carneiro F, Hruban RH, Theise ND. (Eds), International Agency for Research on Cancer, Lyon 2010. p.134.

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK.

Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):13-24

Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.

Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA.

J Clin Oncol. 2012 Nov 10;30(32):3932-8.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators.

Lancet. 2014 Jan 4;383(9911):31-9. doi: 10.1016/S0140-6736(13)61719-5

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group.

Lancet Oncol. 2014 Oct;15(11):1224-35

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA.

J Clin Oncol. 2012 Jun 10;30(17):2119-27.

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

Cunningham D, Tebbutt NC, Davidenko I, et al.

J Clin Oncol. 2015;33:(suppl; abstr 4000).

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA.

N Engl J Med. 2013 Jun 20;368(25):2385-94

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.

N Engl J Med. 2014 Nov 20;371(21):1963-71.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsl E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U.

Ann Oncol. 2013 Jan;24(1):152-60

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruzniewski P; **CLARINET** Investigators.

N Engl J Med. 2014 Jul 17;371(3):224-33.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group.

J Clin Oncol. 2009 Oct 1;27(28):4656-63

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.

Cancer. 2011 Jan 15;117(2):268-75.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruzniewski P.

N Engl J Med. 2011 Feb 10;364(6):501-13.

Multiple Endocrine Neoplasia Type 1.

Giusti F, Marini F, Brandi ML.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015.

2005 Aug 31 [updated 2015 Feb 12].

Hereditary diffuse gastric cancer - pathophysiology and clinical management.

Pinheiro H, Oliveira C, Seruca R, Carneiro F.

Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1055-68.

MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations.

Georgitsi M.

Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):425-37

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, Aractingi S, Grange JD, Poirier-Colame V, Malka D, Soria JC, Mateus C, Robert C.

J Clin Oncol. 2009 Aug 10;27(23):e59-61

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R.

J Neurosurg. 2001 Aug;95(2):190-8.

An extent of resection threshold for newly diagnosed glioblastomas.

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS.

J Neurosurg. 2011 Jul;115(1):3-8

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.

Oncotarget. 2015 Jul 3\

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

Cabrini G, Fabbri E, Lo Nigro C, Dechechchi MC, Gambari R.

Int J Oncol. 2015 Aug;47(2):417-28

IDH1 and IDH2 mutations in gliomas.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.

N Engl J Med. 2009 Feb 19;360(8):765-73